Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing innovative medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange main market, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.
The company’s current focus is on Alcohol Use Disorder (AUD)—affecting over 40 million people across the U.S., UK, and EU4—and Post-Traumatic Stress Disorder (PTSD), which impacts more than 13 million adults in the U.S. and approximately 20 million across the same regions.
Company Details
- Employees
- 5
- Founded
- -
- Address
- London, Gb
- Phone
- 416-907-5644
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- awaknlifesciences.com
- HQ
- London
Solvonis Therapeutics (Formerly Awakn) Questions
Solvonis Therapeutics (Formerly Awakn)'s helpline number is 416-907-5644
Solvonis Therapeutics (Formerly Awakn)'s website is awaknlifesciences.com
Solvonis Therapeutics (Formerly Awakn)'s LinkedIn profile is https://uk.linkedin.com/company/awakn-life-sciences
Solvonis Therapeutics (Formerly Awakn) has
5 employees.
View email and phone details for 5
employees at Solvonis Therapeutics (Formerly Awakn).
Solvonis Therapeutics (Formerly Awakn)'s industry is
Biotechnology Research
Solvonis Therapeutics (Formerly Awakn)'s top competitors are
Compass Pathways,
Cybin Inc,
Lykos Therapeutics,
Mindmed,
Numinus,
Eleusis,
Multidisciplinary Association For Psychedelic Studies (Maps),
Osmind,
Atai Life Sciences,
Mindbloom.
Solvonis Therapeutics (Formerly Awakn)'s categories are Biotechnology Research
Solvonis Therapeutics (Formerly Awakn)'s founding year is 2020
